Becerra-Tomás, N.; Ruiz-Canela, M.; Hernández-Alonso, P.; Bulló, M.; Li, J.; Guasch-Ferré, M.; Toledo, E.; Clish, C.B.; Estruch, R.; Ros, E.;
et al. Glycolysis Metabolites and Risk of Atrial Fibrillation and Heart Failure in the PREDIMED Trial. Metabolites 2021, 11, 306.
https://doi.org/10.3390/metabo11050306
AMA Style
Becerra-Tomás N, Ruiz-Canela M, Hernández-Alonso P, Bulló M, Li J, Guasch-Ferré M, Toledo E, Clish CB, Estruch R, Ros E,
et al. Glycolysis Metabolites and Risk of Atrial Fibrillation and Heart Failure in the PREDIMED Trial. Metabolites. 2021; 11(5):306.
https://doi.org/10.3390/metabo11050306
Chicago/Turabian Style
Becerra-Tomás, Nerea, Miguel Ruiz-Canela, Pablo Hernández-Alonso, Mònica Bulló, Jun Li, Marta Guasch-Ferré, Estefanía Toledo, Clary B. Clish, Ramon Estruch, Emilio Ros,
and et al. 2021. "Glycolysis Metabolites and Risk of Atrial Fibrillation and Heart Failure in the PREDIMED Trial" Metabolites 11, no. 5: 306.
https://doi.org/10.3390/metabo11050306
APA Style
Becerra-Tomás, N., Ruiz-Canela, M., Hernández-Alonso, P., Bulló, M., Li, J., Guasch-Ferré, M., Toledo, E., Clish, C. B., Estruch, R., Ros, E., Fitó, M., Lee, C.-H., Pierce, K., Arós, F., Serra-Majem, L., Liang, L., Razquin, C., Gómez-Gracia, E., Martínez-González, M. A.,
... Salas-Salvadó, J.
(2021). Glycolysis Metabolites and Risk of Atrial Fibrillation and Heart Failure in the PREDIMED Trial. Metabolites, 11(5), 306.
https://doi.org/10.3390/metabo11050306